Specific prognostic biomarkers that have been evaluated in HNSCC include programmed death ligand 1 (PD-L1) expression, tumor mutational burden (TMB), and immune gene signatures within both the tumor and the surrounding tissue [11–18]. The gene discussed is CD274; the disease is neoplasm.